This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jackson, D. V. Articles by Bender, R. A. Search for Related Content PubMed PubMed Citation Articles by Jackson, D. V., Jr. Articles by Bender, R. A.

Cytotoxic Thresholds of Vincristine in a Murine and a Human Leukemia Cell Line in Vitro

Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20205 [D. V. J., R. A. B.], Division of Oncology/Hematology, Bowman Gray School of Medicine, Winston-Salem, North Carolina 27103 [D. V. J.], and Scripps Clinic and Research Foundation, La Jolla, California 92037 [R. A. B.]

L1210 murine leukemia and CEM human lymphoblastoid leukemia cells were exposed to vincristine sulfate in vitro. The response of these cell lines to this agent was measured by the colony-forming ability of L1210 cells in soft agar and inhibition of growth of CEM in suspension culture. Incremental increases of vincristine concentrations in excess of 2 x 10^-9 M produced a progressive reduction of survival of L1210 cells and suppression of CEM growth under the condition of constant drug exposure. A maximum cytotoxic effect was reached with drug concentrations between 10^-8 and 10^-7 M. When L1210 cells were exposed to vincristine for a variable length of time ranging from 0.5 to 24 hr, 10^-7 M produced a noticeable cytotoxic effect following an incubation of only 30 min. A 50% cell kill of L1210 cells and a 50% reduction of CEM cell growth were produced by 10^-7 M following a 1- to 3-hr period of exposure; 6 to 12 hr were required to produce a similar effect at a vincristine concentration of 10^-8 M. Therefore, the antitumor effect of vincristine is critically dependent on both concentration and duration of exposure. These data suggest the possibility that the effectiveness of vincristine as an antitumor agent could be enhanced if methods are developed to prolong exposure of neoplastic tissues for longer periods of time than currently produced by conventional methods of administration.

¹ To whom requests for reprints should be addressed, at Division of Oncology/Hematology, Bowman Gray School of Medicine, Winston-Salem, N. C. 27103.

Received 6/19/78. Accepted 7/25/79.

This article has been cited by other articles:

				A. Y. Bedikian, A. Vardeleon, T. Smith, S. Campbell, and R. Namdari Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J. Clin. Pharmacol., July 1, 2006; 46(7): 727 - 737. [Abstract] [Full Text] [PDF]

				P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]